"Heavy basic, light clinical" will delay the development of innovative drugs in China for 5 to 10 years
China's ability to rely on the current clinical research capabilities and resources to achieve the "health science and technology innovation overall strength in the forefront of the world" proposed in "Healthy China 2030" also faces many challenges. It is recommended to improve the clinical research and development strategy at the national level, increase the degree of emphasis, clearly improve the clinical research ability as one of the goals of medical reform, and set the short-term and long-term goals of clinical research development. Recently, seven drug research institutes jointly released the latest research report “Promoting the Design and Implementation of Clinical Research System and Deepening the Construction of Medical Innovation Ecosystemâ€. The report believes that clinical research is the most important part of the entire medical innovation ecosystem, if clinical research The problem of capacity and resources cannot be solved in time, and the development process of China's innovative medicine industry will be delayed for at least five to ten years. Therefore, it is recommended to improve the clinical research and development strategy at the national level, increase the degree of emphasis, and clearly improve the clinical research ability as one of the goals of medical reform. And set the short-term and long-term goals for clinical research development. "Health China 2030" clearly stated that it is necessary to "eliminate a number of major disease hazards." For many serious and chronic diseases, it is necessary to conduct scientific research on the scientific data of the Chinese population as a reference for evidence-based medicine, so as to continuously improve the level of diagnosis and treatment in China. For many serious diseases with high incidence in China (such as liver cancer, stomach cancer, esophageal cancer and hepatitis B), there is a lack of innovation in the world, and it is even more necessary to explore solutions through Chinese medical workers through clinical research methods. China's ability to rely on the current clinical research capabilities and resources to achieve the "health science and technology innovation overall strength in the forefront of the world" proposed in "Healthy China 2030" also faces many challenges. Taking clinical research resources as an example: the number of institutions that have obtained GCP (Clinical Testing Quality Management Practices) certification in China has not changed significantly from 2014 to 2016, and the 168 new institutions in 2017 have not yet had the scale to carry out clinical trials of innovative drugs. Ability. At the same time, according to the data comparison from 2014 to 2016, the number of articles published by Chinese researchers in the clinical research-based magazines Lancet, New England Magazine and Journal of the American Medical Association is ranked in 12 countries. No. 9, only 2.7% of the United States. In the past 15 to 20 years, China’s government funding for medical science has supported “heavy foundation and light clinicalâ€. Taking the 2016 National Natural Science Foundation funded project as an example, 95% of the topics related to medical science approved for funding are Basic medicine, only 5% is used to support clinical research. Similarly, the 2016 National Key R&D Program launched a total of 299 biomedical related projects in 7 categories, of which only 13% were used for clinical research, and the proportion of government research funds to support clinical research needs to be increased. At present, hospitals and doctors lack motivation to participate in clinical research. For example, some basic research cycles are short, investment is small, and academic articles are easier to publish. In contrast, high-level clinical research often requires large-scale financial support, long trial runs, and higher requirements for researchers and support teams. Moreover, due to the large number of participants, there are even fewer opportunities to sign in the article, and it is difficult to meet the number of articles published for job title promotion. Therefore, researchers are generally less motivated and need to establish a team of medical institutions and researchers to undertake clinical research. Incentive mechanism. The report is sponsored by the China Association of Enterprises with Foreign Investment, Drug Development and Development Industry Committee, China Pharmaceutical Association, Clinical Evaluation Research Committee, Peking University APEC Supervisory Science Center of Excellence, Peking University Clinical Research Institute, China Pharmaceutical Enterprise Management Association, China Chemical Pharmaceutical Industry The Association, China Chamber of Commerce for Import and Export of Medicines and Health Products, was jointly completed under the guidance of more than 40 consultants. (Source: Workers Daily)
The metal Padlock seals include a fixed-length indicative wire hasp and a plastic locking body. The application of a
padlock seals can be : Meters, Doors, Hatches, In-bond Shipments, Bags,
Scales,Tankers,Tote Boxes,Trailers, Airline Bar Boxes, Pouches etc.
The
Plastic Padlock Seals can be marked by heat stamp or laser engraving. A
logo, serial number , barcode , QR code are possible to be personalized
on the seals.
The plastic material for the padlock seals can be PP, PC, ABS. The
transparent padlock only can use PC material. In order to resist the
environment affection, UV additives can be applied to extand the seal
life. Or can be a security feature for identification.
Metal Padlock seals,Padlock Wire Seals,Wire Seals,Metal Padlock Seal Wenzhou Haoshi Light Industrial Products Co., LTD , https://www.economicseals.com